Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Regulatory News (ABC)

  • There is currently no data for ABC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Company Secretary Change

29 Jun 2015 09:24

RNS Number : 4817R
ABCAM Plc
29 June 2015
 



For immediate release

29 June 2015

ABCAM PLC

("Abcam" or "the Company")

Appointment of Chief Legal Officer and Company Secretary

 

Cambridge UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, announces that it has appointed Suzanne Smith in the new role of Chief Legal Officer and Company Secretary, based at Abcam's headquarters in Cambridge, UK, effective from 6 July 2015. Accordingly, Jeff Iliffe will resign from the role of Company Secretary with effect from the same date.

Suzanne will take responsibility for Abcam's licensing, legal, compliance and company secretary activities. The new role has been created in order to help Abcam achieve its global growth objectives, supporting the Company's partnership and acquisition goals.

Suzanne brings a wealth of experience to Abcam with 20 years' global legal, business and leadership experience within the life science industry. She previously held the role of executive director, legal at Actavis plc, where she had responsibility for the leadership of the legal function internationally. Her prior roles include legal director at Genzyme Therapeutics Ltd, general counsel at Phoqus Pharmaceuticals plc and group legal counsel and company secretary at LGC Ltd. Suzanne is a qualified solicitor and holds an LLB law degree from the University of Exeter and an MBA from the Open University.

Alan Hirzel, CEO of Abcam, commented: "We are delighted to welcome Suzanne to Abcam's leadership team. Suzanne's knowledge and experience within the life sciences industry will be a valuable asset to our company."

 

For further information please contact:

Abcam

+ 44 (0) 1223 696 000

Jeff Iliffe, Chief Financial Officer

Laura Taylor, Investor Relations Manager

J.P.Morgan Cazenove - Nominated Adviser & Joint Corporate Broker

+ 44 (0) 20 7742 4000

James Mitford / Alex Bruce - Nominated Adviser

Peel Hunt LLP - Joint Corporate Broker

+ 44 (0) 20 7418 8900

Clare Terlouw / Jock Maxwell MacDonald - Corporate Broking

 

Notes to Editors

About Abcam

Abcam plc is a provider of life science research tools, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.

Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company's catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.

Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices enabling local services, multi-language support and next-day delivery in over 130 countries. The Company was founded in 1998, and now employs over 800 people. Abcam was admitted to AIM in 2005 (AIM:ABC).

To find out more, please visit www.abcam.com 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
COSSEESAUFISEEM
Date   Source Headline
1st Oct 20204:41 pmRNSTotal Voting Rights
25th Sep 20201:33 pmRNSDirector/PDMR Shareholding
18th Sep 20202:19 pmRNSBlock listing Interim Review
18th Sep 20207:54 amRNSDirector/PDMR Shareholding
14th Sep 20207:00 amRNSFull Year Results 2020
11th Sep 202010:34 amRNSNotice of Results
1st Sep 20207:52 amRNSTotal Voting Rights
4th Aug 202012:57 pmRNSTotal Voting Rights
23rd Jul 20207:00 amRNSChange of Adviser
23rd Jul 20207:00 amRNSFull Year Trading Update
2nd Jul 202010:11 amRNSTotal Voting Rights
16th Jun 202012:00 pmRNSDirectorate Change
1st Jun 20209:29 amRNSTotal Voting Rights
11th May 202011:00 amRNSStatement re Update on 2019 AGM Resolution Vote
1st May 202012:24 pmRNSTotal Voting Rights
22nd Apr 202010:11 amRNSHolding(s) in Company
21st Apr 20207:26 amRNSDirector/PDMR Shareholding
20th Apr 202010:19 amRNSHolding(s) in Company
20th Apr 20207:00 amRNSCOVID-19 Update
14th Apr 202010:07 amRNSHolding(s) in Company
9th Apr 20205:33 pmRNSIssue of Shares
2nd Apr 20209:50 amRNSTotal Voting Rights
27th Mar 20203:37 pmRNSHolding(s) in Company
9th Mar 20207:00 amRNSInterim results for 6 months ended 31 Dec 2019
4th Mar 20207:00 amRNSAcquisition of Marker Gene Technologies
2nd Mar 20203:43 pmRNSTotal Voting Rights
2nd Mar 20208:00 amRNSBlock listing Interim Review
4th Feb 202010:49 amRNSTotal Voting Rights
30th Jan 20207:00 amRNSAbcam expands cell engineering capabilities
28th Jan 20202:31 pmRNSHolding(s) in Company
28th Jan 20202:29 pmRNSDirector/PDMR Shareholding
14th Jan 20207:00 amRNSAppointment of Chief Financial Officer
10th Jan 20207:00 amRNSHalf Year Trading Update
2nd Jan 20209:45 amRNSTotal Voting Rights
2nd Jan 20207:00 amRNSTransaction complete between Abcam and Expedeon
19th Dec 201910:05 amRNSHolding(s) in Company
4th Dec 20193:37 pmRNSHolding(s) in Company
2nd Dec 20193:25 pmRNSDirector/PDMR Shareholding
2nd Dec 20199:30 amRNSTotal Voting Rights
21st Nov 201911:42 amRNSHolding(s) in Company
14th Nov 20197:00 amRNSAbcam Capital Markets Event
13th Nov 20194:45 pmRNSResult of AGM
11th Nov 20197:00 amRNSAbcam to acquire proteomics & immunology business
6th Nov 20199:06 amRNSDirector/PDMR Shareholding
1st Nov 201910:55 amRNSTotal Voting Rights
2nd Oct 20194:28 pmRNSHolding(s) in Company
2nd Oct 20191:49 pmRNSDirector/PDMR Shareholding
1st Oct 20192:22 pmRNSTotal Voting Rights
30th Sep 20191:35 pmRNSAnnual Financial Report
26th Sep 20192:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.